Immunic Company Insiders

IMUX Stock  USD 1.20  0.06  5.26%   
Immunic employs about 85 people. The company is managed by 11 executives with a total tenure of roughly 10 years, averaging almost 0.0 years of service per executive, having 7.73 employees per reported executive. Break down of Immunic's management performance can provide insight into the company performance.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Immunic Management Team Effectiveness

The company has return on total asset (ROA) of (0.909) % which means that it has lost $0.909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1624) %, meaning that it created substantial loss on money invested by shareholders. Immunic's management efficiency ratios could be used to measure how well Immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.81 in 2024. Return On Capital Employed is likely to rise to -3.19 in 2024. At this time, Immunic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 70.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.7 M in 2024.
Common Stock Shares Outstanding is likely to rise to about 46.5 M in 2024, despite the fact that Net Loss is likely to grow to (102.9 M).

Immunic Workforce Comparison

Immunic is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,632. Immunic holds roughly 85.0 in number of employees claiming about 5% of equities under Health Care industry.

Immunic Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Immunic insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunic Notable Stakeholders

An Immunic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immunic often face trade-offs trying to please all of them. Immunic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immunic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel VittPresident CEO, DirectorProfile
JD MBAExecutive ChairmanProfile
Jason MBACOO PresidentProfile
Patrick WalshChief OfficerProfile
Glenn CPAChief OfficerProfile
Andreas MDChief OfficerProfile
Inderpal SinghGeneral CounselProfile
Jessica BreuHead CommunicationsProfile
Werner GladdinesChief OfficerProfile
MBA MDEx ChairmanProfile
Hella KohlhofChief Scientific OfficerProfile

About Immunic Management Performance

The success or failure of an entity such as Immunic often depends on how effective the management is. Immunic management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.72)(1.81)
Return On Capital Employed(3.36)(3.19)
Return On Assets(1.72)(1.64)
Return On Equity(3.24)(3.07)
Please note, the imprecision that can be found in Immunic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunic. Check Immunic's Beneish M Score to see the likelihood of Immunic's management manipulating its earnings.

Immunic Workforce Analysis

Traditionally, organizations such as Immunic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immunic within its industry.

Immunic Manpower Efficiency

Return on Immunic Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.1M
Net Loss Per Executive8.5M
Working Capital Per Employee327.1K
Working Capital Per Executive2.5M

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.